2seventy bio fires 40% of staff after reduced Abecma sales forecasts

Preview

来源: Pharmaceutical Technology

Phalguni Deswal

@Phalguni_GD

Preview

来源: Pharmaceutical Technology

Despite restructuring news, the company’s stock rose by 6% in pre-market trading. Image Credit: ProStockStudio / Shutterstock.

Preview

来源: Pharmaceutical Technology

2seventy bio will be reducing its workforce by 40% and firing 176 employees in an effort to cut costs.

One of the main reasons cited for restructuring was the decreased 2023 sales forecasts of Abecma (idecabtagene vicleucel), the company’s only approved therapy. The chimeric antigen receptor (CAR) T-cell therapy, developed in partnership with Bristol Myers Squibb, is expected to generate $470m-$570m less in sales than previously projected, as per 2seventy bio.

Recommended Reports

Preview

来源: Pharmaceutical Technology

ReportsLOA and PTSR Model - 0.75 Percent Nyxol in Nyctalopia (Night Blindness) due to Vitamin A Deficiency GlobalData

Preview

来源: Pharmaceutical Technology

ReportsLOA and PTSR Model - TAK-500 in Triple-Negative Breast Cancer (TNBC) GlobalData

View allCompanies IntelligenceBristol-Myers Squibb CoRegeneron GmbHView all

Still, the company was quick to note that it remains hopeful Abecma sales may improve, considering the expected label expansion for a third indication. The therapy is currently under review with the US Food and Drug Administration (FDA) for the treatment of triple-class exposed relapsed and/or refractory multiple myeloma, with the Prescription Drug User Fee Act (PDUFA) date set for 16 December.

Multiple pharma companies have announced staff layoffs this year following FDA rejections and as a general cash reduction measure due to rising inflation. 2seventy bio expects the layoffs to reduce the cash burden by at least $130m over the next two years.

The company expects the one-time restructuring costs to total approximately $9m and expects its remaining cash reserves to last into 2026. Despite restructuring news, the company’s stock was up 6% in pre-market trading.

In addition to the workforce cuts, 2seventy bio is also limiting funding to two of its Phase I clinical programs, namely bbT369 for treating relapsed and/or refractory B cell non-Hodgkin lymphoma and SC-DARIC-33 for treating acute myeloid leukaemia.

The company also announced the expansion of its partnership agreement with JW Therapeutics to include two CAR-T cell therapies for development. This builds on the previous collaboration with JW Therapeutics and Regeneron to develop T cell-based immunotherapies.

Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva. Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.

Free WhitepaperCell and gene therapies: Pipe dream to pipeline The cell and gene industry is gaining momentum, with a new wave of therapies promising to transform the way doctors treat, and even cure, disease. In this report, Cytiva and GlobalData have collaborated to explore the rise of the cell and gene therapy industries, the current state of the market, present and future opportunities for advancement, and the challenges that lie ahead.By Cytiva Thematic

Preview

来源: Pharmaceutical Technology

-->

By downloading this case study, you acknowledge that GlobalData may share your information with Cytiva Thematic and that your personal data will be used as described in their Privacy Policy

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。